New hope for lymphoma patients: targeted therapy trial launches

NCT ID NCT07355699

Recruiting now Disease control Sponsor: Beijing Tongren Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called orelabrutinib, alone or with another drug (CD20 antibody), in 88 people with untreated marginal zone lymphoma. The goal is to see how well the treatment shrinks or controls the cancer. Participants take the drug daily for 6 cycles, and those with more advanced disease also get an infusion. This is not a cure, but aims to manage the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA (MZL)

Contacts and locations

Locations

Beijing Tongren Hospital
RECRUITING

Beijing, China
Peking Union Medical College Hospital
NOT_YET_RECRUITING

Beijing, China
The First Affiliated Hospital of China Medical University
NOT_YET_RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.